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Abstract: Tumor cell heterogeneity is primarily dictated by mutational changes, sometimes leading
to clones that undergo a metastatic switch. However, little is known about tumor heterogeneity
following chemotherapy perturbation. Here we studied the possible involvement of tumor-derived
extracellular vesicles, often referred to as tumor-derived microparticles (TMPs), as mediators of the
metastatic switch in the tumor microenvironment by hindering cell adhesion properties. Specifically,
we show that highly metastatic or chemotherapy-treated breast cancer cells shed an increased number
of TMPs compared to their respective controls. We found that these TMPs substantially reduce
cell adhesion and disrupt actin filament structure, therefore increasing their biomechanical force
pace, further implicating tumor cell dissemination as part of the metastatic cascade. Our results
demonstrate that these pro-metastatic effects are mediated in part by CD44 which is highly expressed
in TMPs obtained from highly metastatic cells or cells exposed to chemotherapy when compared
to cells with low metastatic potential. Consequently, when we inhibited CD44 expression on TMPs
by a pharmacological or a genetic approach, increased tumor cell adhesion and re-organized actin
filament structure were observed. We also demonstrated that breast cancer patients treated with
paclitaxel chemotherapy exhibited increased CD44-expressing TMPs. Overall, our study provides
further insights into the role of TMPs in promoting metastasis, an effect which is augmented when
tumor cells are exposed to chemotherapy.
Keywords: chemotherapy; breast cancer; adhesion; metastasis; CD44; extracellular vesicles
1. Introduction
Although significant progress has been made in the last decades towards the development of
novel anti-cancer therapies for the treatment of advanced metastatic disease, most cancer types are
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still incurable, with metastasis being the main cause of death. In breast cancer, the most frequently
diagnosed cancer in women, approximately half a million cancer deaths due to metastasis are reported
per year [1]. Although a minority of breast cancer patients are diagnosed with stage IV advanced
metastatic incurable disease, approximately 30% of all breast cancer will develop metastasis within
months and years after diagnosis [2]. Metastasis is a multi-step process that includes cancer cell
dissemination from the primary tumor, intravasation to the blood or lymphatic system, survival in
the circulation, extravasation to a target organ, and seeding and proliferation at a distant site [3,4].
These effects require a tight regulation of the cellular machinery that supports tumor cell detachment
from the primary tumor and their binding to the metastatic site.
Microparticles have recently emerged as having a potentially significant role in tumor progression
and metastasis. Microparticles belong to heterogeneous double layered membrane-coated particles
exerted from cells, called extracellular vesicles (EVs) [5]. EVs encompass lipids, proteins, mRNA,
non-coding RNA, and DNA. EVs have been mostly studied in the context of intercellular communication,
whereby they transfer cargo between cells, including signaling proteins and RNA, as well as stimulate
cells by membrane binding [5,6]. There are three main family members of EVs: apoptotic bodies
(1000–4000 nm in diameter), microparticles (100–1000 nm in diameter), and exosomes (20–100 nm
in diameter) [5,7]. EVs have been shown to affect cancer progression in various ways. For example,
at remote secondary sites, the EVs are taken up by organ-derived cells, thereby preparing the
microenvironment for future tumor cell seeding. These effects are associated with integrins expressed
by EVs, which direct them to specific organs [8]. In melanoma, EVs derived from tumors contribute to the
mobilization of myeloid cells to the pre-metastatic site and support metastasis [9]. Such pre-metastatic
niche formation has been recently reported to be enhanced in response to chemotherapy [10]. At the
primary tumor site, EVs promote tumor progression by transferring oncogenic proteins such as EGFRvIII
between glioblastoma cells [11]. Thus, EVs play a significant role in tumor growth and metastasis.
When focusing on microparticles, it has been shown that tumor-derived microparticles (TMPs)
obtained from multidrug-resistant breast cancer cells support immune evasion by polarizing
macrophages into an inactive state. This process contributes to the colonization of breast cancer
cells at distant sites [12]. In another study, TMPs were shown to selectively transfer p-glycoprotein to
breast cancer cells, supporting their multidrug resistance capacity and therefore contributing to tumor
growth [13]. We have recently demonstrated that breast cancer cells exposed to chemotherapy shed
an increased number of TMPs expressing osteopontin. These TMPs support the mobilization and
tumor homing of pro-angiogenic bone marrow-derived cells (BMDCs), ultimately enhancing tumor
growth and metastasis [14]. However, little is known about the effect of TMPs on the biomechanical
pro-metastatic forces of cells within the primary tumor site, which support their dissemination, and
about the contribution of chemotherapy to this process.
Metastasis is regulated by an abundant number of proteins, which participate in each step of the
metastatic process. Cell adhesion is one of the key factors contributing to the early stage of metastasis,
when tumor cells disseminate from the primary tumor site. To do this, tumor cells reduce their
adhesion ability and increase their biomechanical forces in order to allow their dissemination from the
surrounding microenvironment. CD44 is a transmembrane glycoprotein which is expressed on the cell
surface of many cancer cells [15]. CD44 confers several variant isoforms, some of which are found
to be upregulated in tumor progression [16]. It has been demonstrated that the high expression of
CD44 on cancer cells is associated with increased metastasis [17]. The interaction of CD44 with ECM
ligands such as hyaluronic acid, osteopontin, collagens, and matrix metalloproteinases contributes to
cell migration and invasion and supports metastasis [18]. Furthermore, the transfer of CD44/CD44v6
expressed by EVs supports tumor initiation and progression [19]. Similarly, CD44-expressing EVs also
contribute to metastasis by remodeling the ECM within the primary tumor, supporting tumor cell
invasion [20]. Thus, CD44 is an important regulator for the metastatic process.
Here we show that TMPs from highly metastatic tumor cells or cells exposed to chemotherapy
enhance the metastatic characteristics of low-metastatic recipient cells. These effects include decreased
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focal adhesions, actin cytoskeleton rearrangement, and an increased number of catch/release cycles in
the process of biomechanical force production, all driven by TMPs expressing CD44. Thus, this study
describes a biomechanical mechanism that drives the metastatic switch in chemotherapy-treated tumors.
2. Materials and Methods
2.1. Cell Culture
MDA-MB-231 human breast carcinoma cells, 4T1 murine breast carcinoma cells, and HEK293T
human embryonic kidney cells were purchased from the American Type Culture Collection (ATCC).
The LM2-4 cell line, a lung metastatic variant of the MDA-MB-231 cell line, was kindly provided by
Prof. Robert Kerbel (Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada). 67NR, a low
metastatic variant of the 4T1 cell line, was kindly provided by Prof. Jonathan Sleeman (Medical
Faculty Mannheim, Centre for Biomedicine and Medical Technology Mannheim (CBTM), University of
Heidelberg, Mannheim 68167, Germany). In some cases, cells were fluorescently tagged with green
fluorescent protein (GFP). All cells were used within 6 months of resuscitation. Human cell lines were
cultured in RPMI 1640 (Sigma-Aldrich, Rehovot, Israel) and murine cell lines in Dulbecco’s modified
Eagle’s medium (Sigma-Aldrich). In all cases, medium was supplemented with 5% fetal bovine
serum (FBS), 1% l-glutamine, 1% sodium pyruvate, and 1% streptomycin, penicillin, and neomycin in
solution (10 mg/mL, Biological Industries, Beit, Ha’Emek, Israel). Cells were tested routinely to be
mycoplasma-free. Human cell lines were tested to be authentic or they were used within 6 months
from resuscitation.
2.2. Extraction and Quantification of TMP
The extraction and quantification of TMPs were carried out as previously demonstrated and
validated [13,14,21,22]. Briefly, cells were grown to 80% confluency, at which point medium was
replaced with serum free (SF) medium or SF medium supplemented with 200 nM paclitaxel (PTX),
as previously described [14]. After 48 h, conditioned medium (CM) was collected and centrifuged at
4000× g for 20 min at room temperature (RT) to remove floating cells and apoptotic bodies. Supernatants
were collected and centrifuged at 20,000 g for 1 h at 4 ◦C. The TMP-containing pellet was resuspended
in phosphate buffered saline (PBS) and stored at −80 ◦C until further use. It should be noted that
the dosage of 200 nM PTX for a duration of 48 h in serum-free conditions did not result in cell
death, excluding the possibility that samples were contaminated with apoptotic bodies, as previously
described [14].
TMP quantification was performed using flow cytometry by calculating the ratio between 7.35-µm
counting beads (Calbiochem, Burlington, MA) and the number of events collected in the TMP gate
(approximately 0.6–0.9 µm), as previously described [14,23]. Additional information can be found in
the Supplemental Online Materials.
Quantification and measurement of TMPs by Nanosight NS300 (NanoSight LTD., Malvern, UK)
was performed as previously described [24]. Additional information can be found in the Supplemental
Online Materials.
2.3. Modified Boyden Chamber Assay
The invasion properties of MDA-MB-231 or 67NR cells pre-exposed to different TMP conditions
were evaluated in Matrigel-coated Boyden chambers as previously described [25]. Additional
information can be found in the Supplemental Online Materials.
2.4. Cell Spreading Assay
TMPs were pre-exposed to 1 µg/mL IgG or anti-CD44 (BioXcell, West Lebanon, NH) for 1 h,
followed by extensive washing, in which a volume of 100 times PBS was used. The TMPs were then
added to MDA-MB-231 GFP+ cultures and incubated for 24 h. Subsequently, the cells were trypsinized
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and re-plated on fibronectin-coated glass plates. Time-lapse movies were generated from images
acquired every 5 min for a total of 4 h using an ImageXpress Micro Confocal system (Molecular Devices,
San Jose, CA). The percentage of cells spreading over fibronectin was analyzed using FIJI, as previously
described [26].
2.5. Cell Viability AlamarBlueTM Assay
The metabolic indicator dye AlamarBlueTM (Serotec Ltd., Oxford, UK) was used to determine
cell viability, as previously described [27]. Additional information can be found in the Supplemental
Online Materials.
2.6. Pillar Fabrication
Pillar fabrication was performed as previously described [26,28]. Briefly, PDMS (Sylgard 184, Dow
Corning; 10:1 base to curing agent ratio) was poured over silicon molds with wells that were 1.3 µm
deep, 0.5 µm wide, and spaced 1 µm apart (center-to-center distance). The molds were then flipped
over onto glass-bottom dishes (no. 0 glass coverslip, Cellvis), which were then placed at 60 ◦C for 12 h
to cure the PDMS. The molds were peeled off from the plates while immersed in pure ethanol, which
was then replaced by PBS. The pillars were coated with fibronectin (10 µg/mL, 1 hr, 37 ◦C). To measure
cellular forces on the fibronectin-coated pillars, serum-starved MDA-MB-231 cells were cultured for
24 h in the presence of 100,000 TMPs obtained from untreated or PTX-treated MDA-MB-231 cells, or
from untreated or PTX-treated LM2-4 cells. The cells were then spread on the pillar arrays and imaged
at 37 ◦C using a Leica DMIRE2 microscope (Leica Microsystems, Wetzlar, Germany), 100× 1.4 NA oil
objective, and a CCD camera (QImaging Retiga EXi). Analyses of pillar movements was performed
with ImageJ (V.1.51, National Institutes of Health, Bethesda, MD, USA) using the Nano Tracking
plugin as previously described [26]. Pillar displacement curves were generated using Matlab (V.9.4,
MathWorks, Natick, MA, USA). Analyses of pillar releases by the cells was performed on the pillar
displacement curves using the ‘findpeaks’ function in Matlab. All peaks identified were categorized
into bins ranging from 1 to 12 nm, and the number of releases per second was calculated for each of
these bins. For each condition >30 pillars from >3 cells were analyzed.
2.7. CD44 Short Hairpin RNA
Several different short hairpin RNA (shRNA) sequences specific to human CD44 or a scrambled
control sequence were cloned into the GIPZ Lentiviral Human shRNA plasmid (Horizon Discovery,
Lafayette, CO, USA), as previously described [29]. Subconfluent LM2-4 cells were transfected with
shRNA plasmids using lipofectamine reagent (Thermo Fisher Scientific, MA, USA) according to the
manufacturer’s instructions. Forty-eight hours post-transfection, cells were incubated in growth
medium containing puromycin (1 µL/mL) for the selection of stable transfectants. After 3 weeks
of selection, the protein level of CD44 was evaluated by flow cytometry using appropriate controls.
Two independent CD44-depleted clones generated from the pooled cells were selected for this study.
2.8. Western Blot
Paxillin and phospho-paxillin analysis was performed as follows. MDA-MB-231 cells were
pre-exposed to 100,000 TMPs for 24 h, and then seeded on a fibronectin (20 µg/mL) coated plate
overnight. Subsequently, the cells were lysed in Hepes 50 mM PH-7.5, EDTA 4 mM, Triton 1%,
0.5 mg/mL Na3VO4, and 4.5 mg/mL Na2P2O7 and lysates were subjected to SDS-PAGE. Proteins
were electro-transferred to nitrocellulose membranes, which were then probed with polyclonal
rabbit anti-paxillin (1:1000; catalog number 2542, Cell Signaling Technologies, Danvers, MA, USA),
anti-phospho-paxillin (1:1000; catalog number 2541, Cell Signaling Technologies), or anti-GAPDH
(1:5000, catalog number sc-25778, Santa Cruz Biotechnology Inc., Dallas, TX, USA). GAPDH was used
for loading controls. All experiments were performed in triplicate.
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2.9. Tumor-Derived Microparticle Proteomics
TMP proteomics were assessed and analyzed in accordance with the previously described
method [30]. Briefly, TMPs were isolated by multiple centrifugations of conditioned media from
MDA-MB-231 and LM2-4 cells cultured in serum-free media in the presence or absence of PTX,
as described above. Pellets were immediately resuspended in 200 µL of lysis buffer (6 M urea, 2 M
thiourea in 0.1 M Tris pH 7.6). Protein concentration was calculated based on the Bradford assay,
and 10 µg of each sample was used for the analysis. The proteins were reduced using 1 mM DTT
and alkylated using 5 mM iodoacetamide, followed by overnight in-solution trypsin/LysC digestion.
The peptides were acidified with 0.1% TFA and purified on C18 stageTips [31]. A total of three
biological replicates were prepared for each system, some of which were analyzed with two technical
replicates, and were later combined into a single data point.
Resulting peptides were analyzed by LC-MS/MS on the EASY-nLC1000 UHPLC system (Thermo
Fisher Scientific) coupled to the Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific).
The peptides were separated using a gradient of 140 min (technical replicate I) or 240 min (technical
replicate II) of water-acetonitrile on a 50 cm EASY-spray column. Data were acquired using a top-10
method in a data-dependent mode. Resolution values were 70,000 and 17,500 in the MS and MS/MS
scans, respectively.
MS raw files were processed using MaxQuant version 1.5.6.9 [32] and the Andromeda search
engine [33]. MS/MS spectra were searched against the human uniprot database on a forward and
decoy database with 1% false discovery rate for both the protein and the peptide levels. The ‘match
between runs’ option was enabled to transfer identifications between runs. The label-free algorithm
was used for protein quantification. Technical replicates were averaged into a single biological
replicate during the MaxQuant data processing. The proteinGroups output was further analyzed using
Perseus software [34]. Label-free quantification (LFQ) intensity values [35] were log2 transformed.
Each comparison (MDA-MB-231 vs. MDA-MB-231 PTX or MDA-MB-231 vs. LM2-4) was processed
separately following data filtration that kept only those proteins that were quantified in at least two
of the three replicates in at least one of the sample groups. Student’s t-test was performed with
permutation-based false discovery rate (FDR) correction with a cutoff of 0.1 and S0 correction of
0.2 [36]. Enrichment analysis was done using the Fisher exact test with an FDR cutoff of 0.02. Principal
component analysis (PCA) was performed following data imputation, by replacing the missing values
with values that formed a normal distribution with a downshift of 1.6 standard deviations and a width
of 0.4 of the original data distribution.
2.10. Ex Vivo Pulmonary Metastasis Assay
The ex vivo pulmonary metastasis assay (PuMA) was performed as previously described [37,38].
Additional information can be found in the Supplemental Online Materials.
2.11. Blood Samples from Cancer Patients
The study was approved by the hospital’s Ethics Committee (Ha’Emek medical center),
and written informed consent was obtained from all involved patients, in compliance with the Helsinki
declaration for human studies. Patients with localized breast carcinoma were treated by neoadjuvant
chemotherapy (before tumor removal), consisting of adriamycin and cyclophosphamide followed by
PTX chemotherapy, at the Ha’Emek Medical Center, Afula, Israel. Blood was collected in 5-mL sodium
citrate (3.2%) tubes before the first cycle of PTX chemotherapy and 24 h post-treatment (n = 15). Plasma
was obtained by centrifugation at 1000 g for 10 min at RT. Subsequently, platelet-poor plasma (PPP) was
extracted by plasma centrifugation at 3000 g for 5 min at RT, as previously described [39]. This procedure
eliminated most of the platelets (<10,000 per µL). To ensure purified PPP, another centrifugation
(3000 g for 5 min) was performed on separated PPP at RT. Subsequently PPP was stored at −80 ◦C.
Thawed PPP was centrifuged at 20,000 g for 1 h, and the pellet was resuspended in PBS. Anti-MUC-1
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antibody and anti-CD44 antibody were added according to the manufacturer’s instructions and were
subsequently analyzed by flow cytometry as previously described [14]. A fluorescence-minus-one
control (FMO) was used to determine nonspecific binding of antibodies, as previously described [40].
2.12. Immunostaining and Imaging
Serum-starved cells were cultured for 24 h in the presence of 100,000 TMPs obtained from
untreated or PTX-treated cells, as indicated in the text. In some experiments, TMPs were cultured with
cells for 24 h in serum-free medium in the presence of anti-CD44 antibodies (1 µg/mL). Cells were
rigorously washed in PBS (100-fold volume), and then seeded on fibronectin-coated plates (20 µg/mL
fibronectin, Biological Industries). After 4 h, cells were fixed using 4% paraformaldehyde (PFA) and
immunostained with a primary anti-vinculin antibody (1:100, Sigma-Aldrich) and Cy2-conjugated
secondary antibody. Actin was stained with Alexa 488 conjugated phalloidin (1:100, Invitrogen,
Carlsbad, CA, USA). Images were acquired with a LSM 700 Zeiss confocal microscope (Zeiss Ltd.
Oberkochen, Germany).
2.13. Statistical Analysis
Data are presented as mean ± standard error (SE). All in vitro studies were performed at least
in three biological replicates. The in vivo studies were performed twice. Statistically significant
differences were assessed by one-way ANOVA, followed by the Tukey post-hoc test (when comparing
between more than two groups) using GraphPad Prism (V.6, La Jolla, CA, USA). When applicable, an
estimate of variance was performed and statistical significance comparing only two sets of data was
determined by the two-tailed Student’s t-test. Significance was set at values of p < 0.05, and designated
as follows: * p < 0.05; ** p < 0.01; *** p < 0.001.
3. Results
3.1. TMPs from Highly Metastatic or Chemotherapy-Treated Tumor Cells Induce Tumor Cell Invasion
To study the effect of TMPs on the metastatic potential and the adhesion properties of tumor cells,
we compared TMPs from MDA-MB-231 cells with their highly metastatic variant, LM2-4 cells [41], or in
the presence or absence of PTX chemotherapy. TMPs were extracted from the medium and quantified
by flow cytometry and NanoSight. Although the number of TMPs extracted from highly metastatic
cells or from cells exposed to chemotherapy was higher than control cells, as previously reported [10,14],
their size was not significantly different as evaluated by NanoSight (Figure S1). Based on their size,
we ruled out the possibility that some of the TMPs detected are apoptotic bodies, as also previously
reported [14].
We next postulated that TMPs from highly metastatic cells or from cells exposed to chemotherapy
could augment the metastatic potential of low-metastatic cells. To this end, TMPs were extracted from
MDA-MB-231 and LM2-4 cells which had been treated with PTX or the vehicle control. Subsequently,
these TMPs were cultured with low-metastatic MDA-MB-231 cells for 24 h and further analyzed for
invasion properties using the Boyden chamber assay. TMPs from PTX-treated MDA-MB-231 cells
enhanced the invasive properties of MDA-MB-231 cells in comparison to control cultures, including
TMPs from non-treated MDA-MB-231 cells or serum-free conditions. Furthermore, MDA-MB-231
cells cultured with TMPs from control or PTX-treated LM2-4 cells exhibited the highest invasive
ability (Figure 1A,B). Notably, TMPs from PTX-treated cells displayed induced invasion properties
regardless of the metastatic potential of the tumor cells, implicating a potent effect of chemotherapy on
TMP-induced cell invasion. Similar results were observed when using 4T1 highly metastatic cells and
their low metastatic 67NR cells (Figure S2). Of note, TMPs had no effect on cell proliferation (Figure S3).
Taken together, these results suggest that TMPs affect tumor cell invasion properties.
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3.2. TMPs from Highly Metastatic or Chemotherapy-Treated Tumor Cells Inhibit Tumor Cell Seeding
We next sought to test if TMPs affect the seeding of low metastatic cells in distant tissues.
We therefore performed an ex vivo pulmonary metastasis assay (PuMA), which primarily evaluates
the seeding potential of tumor cells in the lungs [38]. GFP-expressing MDA-MB-231 cells pre-cultured
for 24 h with TMPs from vehicle- or PTX-treated MDA-MB-231 or LM2-4 cells were injected through
the tail vein of naïve mice to perform the PuMA. The PuMA can be used a method to test the ability of
cells to adhere to a tissue, therefore it is suitable to test the early stage of metastasis, when tumor cells
detach from the primary tumor microenvironment. We found that tumor cell seeding represented by
the number of GFP+ foci in the lungs was reduced when the MDA-MB-231 cells were pre-cultured with
TMPs from PTX-treated MDA-MB-231 cells or with TMPs from vehicle- or PTX-treated LM2-4 cells
(Figure 2A,B). These results were also supported by flow cytometry analysis. Specifically, a reduced
percentage of GFP+ cells in the whole lung tissue was observed in mice injected with MDA-MB-231
cells pre-cultured with TMPs from PTX-treated MDA-MB-231 cells or with TMPs from vehicle- or
PTX-treated LM2-4 cells compared to control MDA-MB-231 cells (Figure 2C). Importantly, the short
time-interval between cell injection and animal sacrifice suggests that the TMPs lowered the cells’
adhesive ability. These results implicate an early process of metastasis at the primary tumor site where
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the cells detached from their surrounding microenvironment. To support these results, we found that
cells exposed to TMPs from PTX-treated MDA-MB-231 cells or to TMPs from vehicle- or PTX-treated
LM2-4 cells spread to a much lower extent when seeded on fibronectin-coated plates, compared to
control conditions (Figure 2D,E). This property directly relates to the inability to form strong cell-matrix
adhesions [26]. Once again, TMPs from PTX-treated cells displayed similar reduced tumor cell adhesion
properties, regardless of the metastatic potential of the tumor cells, therefore suggesting a strong effect
of chemotherapy on TMPs which hinder cell adhesion.
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Figure 2. TMPs from highly metastatic cells or cells exposed to chemotherapy decrease tumor cell
seeding. (A–C) GFP-positive MDA-MB-231 cells cultured with serum-free medium or TMPs from
MDA-MB-231 or LM2-4 cells exposed to PTX or vehicle control were assessed for their seeding
properties using the ex vivo pulmonary metastasis assay (PuMA), as described in Materials and
Methods. Lung sections (n = 4 mice/group) were imaged (A) and the number of metastatic foci were
counted (B). Scale bar, 0.2 cm. White arrows point at metastatic foci only in the serum-free group.
The percentage of metastatic cells in the lungs was also assessed by flow cytometry after the lung sections
underwent single cell suspension (C). (D,E) Cells (treated as in A–C) were seeded on fibronectin-coated
plates. Cell spreading was then immediately assessed by time-lapse microscopy, in which the area of
cell spread was displayed. Representative images are shown in (D). Scale bar, 20 µm. Cell cytoplasmic
membrane and nucleus are drawn in black lines. The percentage of spreading cells when cultured on
fibronectin is shown in (E). n = 3 repeats/group with the assessment of ~100 cells/repeat. * differences
compared to MDA-MB-231 control group, *, p < 0.05, as assessed by one-way ANOVA followed by
Tukey post-hoc test.
3.3. TMPs from Highly Metastatic or Chemotherapy-Treated Tumor Cells Inhibit Cellular Adhesion and
Destroy Actin Filaments
Metastatic cells acquire the ability to detach from the primary tumor by inhibiting adhesion
molecules and rearranging the actin cytoskeleton to promote the migratory properties [42]. To study
the effect of TMPs on the cell adhesion, MDA-MB-231 cells were cultured for 24 h in the presence
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of TMPs from vehicle- or PTX-treated MDA-MB-231 or LM2-4 cells. Then, cells were seeded on
fibronectin-coated plates. After 4 h, cells were fixed and stained with an anti-vinculin antibody
and fluorescently-labeled phalloidin to label focal adhesions by vinculin expression and the actin
cytoskeleton, respectively. A decreased number of adhesions in cells cultured with TMPs from
PTX-treated MDA-MB-231 cells or with TMPs from vehicle- or PTX-treated LM2-4 cells were observed
based on vinculin expression (Figure 3A,B). In addition, cell area was reduced in the presence of
TMPs from all groups in comparison to control cells cultured in the absence of TMPs (Figure 3C).
Lastly, cells cultured with TMPs from PTX-treated MDA-MB-231 cells or with TMPs from vehicle- or
PTX-treated LM2-4 cells demonstrated less organized and elongated actin stress fibers. These fibers
were displayed with shorter actin filaments positioned in multiple directions, compared to those
observed in control cells (Figure 3D). Thus, TMPs support metastatic cell characteristics by means of
downregulating the formation of mature adhesion plaques and less organized actin cytoskeleton.
Cells 2020, 9, 2269 10 of 20
Cells 2020, 9, x 10 of 20 
 
 
Figure 3. TMPs from highly metastatic cells or cells exposed to chemotherapy decrease focal 
adhesions and disrupt filament structure. (A–C) MDA-MB-231 cells cultured with TMPs from MDA-
MB-231 or LM2-4 cells exposed to PTX or vehicle control were seeded on fibronectin-coated plates to 
assess focal adhesion plaques by vinculin immunostaining (green). MDA-MB-231 cells cultured with 
Figure 3. TMPs from highly metastatic cells or cells exposed to chemotherapy decrease focal
adhesions and disrupt filament structure. (A–C) MDA-MB-231 cells cultured with TMPs from
Cells 2020, 9, 2269 11 of 20
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to assess focal adhesion plaques by vinculin immunostaining (green). MDA-MB-231 cells cultured
with serum-free (SF) medium served as a control. Representative images (left panel) with ×16 zoom
micrographs (right panel) are shown. Scale bar, 20 µm. White arrows point at focal adhesion plaques
in the serum-free group (A). The number of focal adhesions per cell was quantified (B). Cell area was
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actin filament structure. Representative images are shown (right panel) with ×16 zoom micrographs
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3.4. TMPs Increase the Pace of Metastatic Cell Biomechanical Forces
Since there is reciprocal regulation between adhesions and their associated force-producing actin
cytoskeleton [43], we sought to determine which of these structures was affected by TMPs, thereby
decreasing adhesion and promoting cell motility. To test this, we evaluated pillar displacement when
using MDA-MB-231 cells in different conditions, as demonstrated in Figure 4A. Specifically, when
MDA-MB-231 cells were cultured with TMPs from LM2-4 or from PTX-exposed cells, they pulled on
the pillars at a similar pace compared to control cells. However, they could not maintain their hold,
leading to repeated pull/release cycles that occurred at a higher rate in comparison to control cells
(Figure 4B), thus demonstrating a significant increase in the average number of pillar releases per
second (Figure 4C). Since defects in cytoskeletal assembly lead to changes in the rate of force application,
whereas defects in adhesions lead to their breakage [26], we concluded that exposure to TMPs from
LM2-4 or from PTX-exposed cells directly decreases cell adhesion properties, rendering the adhesions
too weak to withstand cytoskeletal forces and prevent the formation of stress fibers. Furthermore,
Western blot analysis of cell lysates revealed significantly lower adhesion-associated paxillin signaling
in cells cultured with TMPs from PTX-treated MDA-MB-231 cells or with TMPs from vehicle- or
PTX-treated LM2-4 cells (Figure 4D,E). These results suggest that adhesion is reduced in cells exposed
to TMPs from PTX-treated cells or highly metastatic cells. Overall, our results demonstrate that TMPs
from PTX-treated low metastatic cells or from highly metastatic cells (regardless of chemotherapy
treatment) disrupt cell adhesion, which is consistent with cell dissemination and an increased ability
to invade.
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Figure 4. TMPs from highly metastatic cells or cells exposed to chemotherapy increase the pace of
cell biomechanical forces and inhibit focal adhesion signaling. (A–C) MDA-MB-231 cells cultured
with TMPs from MDA-MB-231 or LM2-4 cells exposed to PTX or vehicle control were applied on a
pillar assay, as described in Materials and Methods. MDA-MB-231 cells cultured with serum-free
medium (SF) were used as a control. (A) Left: Example of a cell spreading on an array of 0.5 µm
diameter fibronectin-coated pillars (see illustration on the right). (B) Typical pillar displacement curves.
(C) Histograms presenting the average number of pillar releases per second binned according to
the size of the release. Each of the control conditions was significantly different than the conditions
in which the cells were exposed to TMPs from LM2-4 cells or from cells exposed to PTX (α < 0.01;
Kolmogorov–Smirnov test). n = 8–10 repeats/group. (D–E) Cells treated as above were seeded on
fibronectin-coated plates to evaluate phospho-paxillin (P-Pax) and total-paxillin (Pax) expression
by Western blot. GAPDH was used as a loading control (D). The ratio between P-Pax over Pax
was calculated based on densitometry, and presented as fold change, for three biological repeats (E).
n = 3 repeats/group. * differences compared to MDA-MB-231 control group, * p < 0.05, as assessed by
one-way ANOVA followed by Tukey post-hoc test.
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3.5. Proteomic Analysis of TMPs
We next undertook a proteomic approach to identify factors within TMPs that affect cell adhesion,
when the major focus was placed on adhesion-related proteins. To this end, TMPs were isolated from
MDA-MB-231 and LM2-4 cells (untreated or treated with PTX) and processed for high-resolution
mass-spectrometry-based proteomic analysis. Overall, 5209 proteins were identified, with control
MDA-MB-231 TMPs exhibiting the lowest number of proteins (Table S1). PCA further reflected the
large variation between control MDA-MB-231 TMPs and all other TMP groups (Figure 5A). We then
performed two comparisons. In the first, we compared the proteomes of TMPs derived from control
and PTX-treated MDA-MB-231 cells. In the second, we compared the proteomes of TMPs derived
from control MDA-MB-231 cells and untreated LM2-4 cells. Over 300 significantly altered proteins
were detected in each comparison (Figure 5B,C). When specifically focusing on adhesion membrane
proteins of which the levels were significantly changed, 15 proteins were common to both comparisons
(Figure 5D). Fourteen of these proteins were higher in MDA-MB-231 control TMPs. Interestingly, out of
the 15 cell adhesion proteins common to both comparisons, only one, CD44, was significantly increased
in TMPs from PTX-treated MDA-MB-231 or untreated LM2-4 cells (Figure 5D). Its intensity in these
TMPs was over two-fold higher than in TMPs derived from control MDA-MB-231 cells (Figure 5E).
Altogether, these results suggest that CD44, probably among other proteins that are significantly
differentially expressed between the various TMP groups, is a possible co-effector that can potentially
account for the disruption of cell adhesion induced by TMPs.
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Figure 5. CD44 is a differentially expressed protein found in highly metastatic and PTX-treated
TMPs. TMPs collected from MDA-MB-231 or LM2-4 cells exposed to PTX, or not, were analyzed by
mass spectrometry. (A) Principal component analysis shows clear separation between MDA-MB-231
control and the rest of the samples. (B,C) Heatmap (left) and volcano plot (right) for the comparison
between control and PTX-treated MDA-MB-231 (B) or control MDA-MB-231 and LM2-4 (C). In blue-
“cell adhesion” proteins based on Gene Otology Biological Process category. (D) t-test difference
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(log2 scale) of the “cell adhesion” proteins that were common to both comparisons. (E) CD44 label-free
quantification (LFQ)-intensity in MDA-MB-231 and LM2-4 cells with and without PTX. The proteomic
analysis was performed when n = 3 repeats / group. All the results and graphs presented are statistically
significant calculated by t-test and false discovery rate (FDR) test described in Materials and Methods.
3.6. CD44-Expressing TMPs Decrease Cell Adhesion and Support Tumor Cell Metastatic Properties
CD44 is a glycoprotein known to participate in cell adhesion and migration [44,45]. Therefore,
increased levels of CD44 in TMPs may explain the TMP-induced increased adhesive and invasive
properties of tumor cells. To test this, TMPs derived from untreated or PTX-treated MDA-MB-231 or
LM2-4 cells were incubated with CD44 blocking antibodies or IgG control antibodies for 24 h. Excess
antibodies were removed by rigorous washing when adding a 100-fold volume of PBS to the sample,
followed by centrifugation to obtain TMPs. Subsequently, the TMPs were added to MDA-MB-231
cultures, and invasive and adhesive properties were assessed. Pre-treating TMPs with anti-CD44
antibodies restored the invasive properties of TMP-exposed tumor cells to control levels (Figure S4A,B).
Similar results were obtained when TMPs from 4T1 cells were pre-treated with anti-CD44 antibodies
and subsequently cultured with 67NR (low metastatic) cells (Figure S4C,D).
Next, TMPs pre-treated with anti-CD44 were added to MDA-MB-231 cultures, and the number
of focal adhesions, assessed by vinculin, cell area, efficiency of cell spreading, and the phenotype
of actin stress fibers, was evaluated. Blocking CD44 on TMPs from highly metastatic cells or
from cells exposed to chemotherapy restored the conditions found in control MDA-MB-231 cells.
Specifically, CD44 inhibition on TMPs increased focal adhesion plaques assessed by vinculin, cell area,
and percentage of cell spreading (Figure 6A–D). Notably, the cell size reduction noticed in MDA-MB-231
cells exposed to TMPs from PTX-treated or LM2-4 cells is in line with cell spreading, demonstrated
in Figure 2D. Furthermore, TMPs in which CD44 was inhibited resulted in rearrangement of actin
stress fibers, mimicking those found in control serum-free conditions (Figure 6E). Similar results were
obtained when TMPs from highly metastatic cells were knocked down for CD44 and subsequently
were added to MDA-MB-231 cultures. Specifically, clones 1 and 2 demonstrated an increased number
of focal adhesion plaques and better organization of actin filaments when compared to scrambled
control cells (Figure S5). Taken together, these results further indicate that CD44-expressing TMPs
contribute to the inhibition of cell adhesion and cytoskeleton re-arrangement, and thus enhance the
metastatic properties of tumor cells.
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control were incubated with anti-CD44 (5 µg/mL) or control IgG and subsequently cultured with
MDA-MB-231 cells. As a control, MDA-MB-231 cells were cultured alone in serum-free medium (SF).
(A–C) The cells were seeded on fibronectin-coated plates to assess focal adhesion plaques by vinculin
immunostaining (green). Representative images are shown (left panel) with ×16 zoom micrographs
(right panel). Scale bar, 20 µm. White arrows point at focal adhesion plaques only in the serum-free
group (A). The number of focal adhesions per cell was quantified (B). Cell area was calculated (C).
n = 10–11 fields/group. (D) Cell spreading was analyzed with time-lapse microscopy. The percentages
of spreading cells per field are shown. n =5 repeats/group. (E) Cells as in (A–C) were stained with
phalloidin (green) to assess actin filament structure. Representative images are shown (right panel)
and ×16 zoom micrographs (left panel). Scale bar, 20 µm. n = 5 fields/group. * differences compared
to MDA-MB-231 control group, * p < 0.05; ** p < 0.01; *** p < 0.001, # differences between IgG and
anti-CD44 of the same group, as assessed by one-way ANOVA followed by Tukey post-hoc test.
3.7. TMPs Expressing CD44 were Increased in Breast Cancer Patients Treated with Chemotherapy
To further investigate the possibility that TMPs expressing CD44 could be found in breast cancer
patients following chemotherapy, we collected plasma samples from 15 breast cancer patients at
baseline or 24 h after PTX chemotherapy administration. We used MUC-1 as an epithelial breast
carcinogenic marker, known also to be expressed on TMPs [14]. The number of MUC-1+/CD44+ TMPs
detected in plasma samples from 12 out of 15 breast cancer patients post-chemotherapy was 3–4-fold
higher than those at baseline (Figure 7A,B). Taken together, the data suggest that chemotherapy induces
CD44 expression on TMPs and, as a result, may contribute to tumor cell aggressiveness.
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Figure 7. Elevated CD44 expression in peripheral TMPs from breast cancer patients who underwent
chemotherapy. (A,B) Blood was collected from breast cancer patients at baseline, and 24 h after the
first cycle of paclitaxel therapy (n = 15). The percentage of TMPs (expressing both MUC-1 and
CD44) was evaluated by flow cytometry in baseline and post-chemotherapy platelet-poor plasma
samples. Fold-increase of TMPs (MUC-1+/CD44+) was calculated relative to baseline levels, and found
to be statistically significant (p < 0.05) using the non-parametrical Wilcoxon signed-rank test (A).
Representative dot plots of the flow cytometry analysis are shown (B). * p < 0.05.
4. Discussion
Metastasis is the main cause of death in cancer patients and is still a major obstacle for the
success of therapy. Treatment protocols involve chemotherapy, radiation, surgery, or their combination.
These protocols have shown clinical benefits, yet resistance is common and recurrence following
chemotherapy is usually more aggressive [46,47]. This study provides a suitable explanation for tumor
cell aggressiveness in response to chemotherapy. Specifically, we demonstrate that TMPs originating
from highly metastatic or chemotherapy-exposed tumor cells mediate a paracrine effect that decreases
cell adhesion and rearranges the actin cytoskeleton. These effects promote early-stage metastatic
properties in recipient low metastatic tumor cells (Figures 2 and 3). To strengthen the fact that cell
adhesion is decreased, we used the ex vivo pulmonary metastasis assay, which specifically tests the
seeding properties of tumor cells, namely, their ability to adhere to the lung tissue. Although one
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would expect an increased number of metastatic foci in the lung sections of the PuMA, the fact that
we observed a reduced number of metastasis (Figure 2A) strengthens our assumption that the major
effect of TMPs is on reduced cell adhesion properties. Reduced cell adhesion is the early process
required for the dissemination of tumor cells from the primary tumor site [48]. These results further
demonstrate that TMPs support different stages of the metastatic cascade. Furthermore, we should
note that our study focused on the in vitro changes in tumor cell characteristics in the presence of
TMPs, yet there are several studies which reported that reduced adhesion of tumor cells supports early
stage of metastatic properties [48]. Additional in vivo studies can strengthen these conclusions by
testing whether TMPs originating from highly metastatic clones or following chemotherapy within the
primary tumor microenvironment, are directly associated with increased metastasis in distant sites.
Taken together, our results provide further support for the role of TMPs in promoting metastasis.
To further identify the possible mechanism for TMP-induced tumor cell metastatic properties,
we have undertaken an unbiased proteomic approach to analyze the expression of various proteins
associated with adhesion. We demonstrate that the pro-metastatic effects of TMPs are associated
with the expression of CD44, a non-oncogenic protein (Figure 5). EVs expressing CD44 have
been shown to promote tumor cell aggressiveness and metastasis mainly by contributing to the
pre-metastatic niche [19,49]. Here we found that TMPs expressing CD44 contribute to metastatic tumor
cell characteristics in part by disrupting the actin cytoskeleton filament structure, inhibiting focal
adhesion plaques and cell spreading, reducing contractility, and downregulating adhesion-related
signaling measured by phospho-paxillin (Figures 3 and 4). While these effects clearly contribute to
the understanding of the extracellular function of CD44, further investigation is needed regarding
the intracellular domain of CD44. Specifically, it has been shown that the intracellular domain of
CD44 recruits actin binding complexes such as ezrin, radixin, moesin (ERM), and ankyrin [50]. These
complexes are associated with intracellular signaling via Ras-MAPK, Wnt, and PI3K [19], and can thus
contribute to the metastatic characteristics of tumor cells by other mechanisms. Notably, although our
studies have focused on specific adhesion molecules, based on the proteomic analysis it is plausible that
other molecules expressed by TMPs may affect cell adhesion properties, including specific extracellular
matrix-associated enzymes. Thus, additional studies in this direction will provide further insights into
the overall effects of TMPs on tumor cell metastatic characteristics.
Elevated CD44 expression levels were also found in TMPs from breast cancer patients treated with
PTX (Figure 7). When analyzing their plasma samples, we focused on MUC1+ EVs that are known to
originate from tumor cells in various malignancies, suggesting that they are TMPs [14,51]. We have
previously demonstrated that the number of TMPs from breast cancer patients increased following
chemotherapy [14]. These results are supported by our current study, in which we demonstrate
that tumor cells exposed to chemotherapy shed an increased number of TMPs (Figure 1). Clinically,
we found that the percentage of TMPs expressing CD44 was increased in plasma samples from breast
cancer patients following chemotherapy when compared to baseline levels. Taken together, our in vitro
findings support the observations found in breast cancer patients.
In summary, we describe a mechanism whereby CD44-expressing TMPs affect tumor cell
metastatic characteristics by inhibiting cell adhesion properties. This effect is augmented in response
to chemotherapy, which can explain the potential increase in metastasis. Indeed, breast cancer
patients treated with neoadjuvant chemotherapy may exhibit an increased tumor microenvironment
of metastasis (TMEM). TMEMs promote the dissemination of tumor cells from the primary tumor
site [52]. It is plausible that combining chemotherapy with agents that inhibit CD44 on TMPs may
reduce the potential for metastasis, and therefore can serve as a strategy to inhibit the possible risks of
chemotherapy-induced metastasis in breast cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/10/2269/s1,
Figures S1–S5, Table S1.
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